Equity
€10,837 from €189,486 in 2022
Equity fell by 94% in 3 years.
CREA MEDIC
Lifetime
6 annual accounts with figures on one time axispeak €247,767 (2023)
€210,207▼ 5.4%
peak €186,449 (2023)
€156,935▼ 4.8%
peak €189,486 (2022)
€10,837▼ 0.6%
€392,400▲ 9.7%
Board1 name since 2020
1 director
Documentsfilings and deeds
24-03-2026129 days before the deadline
2025micro format
Dividend €157,000
Key points
from the 2025 annual accountsDebts
€392,400 97% of the balance sheet
Suppliers 0%Taxes and wages 6%Other 94%
Position in the sector
2.7%
Lower solvency than 92% of companies in human health. Sector median 63.0% · 21,311 companies.
Checked score
Bankruptcy probability within 12 months
Financial strength
Score breakdown
Comparable companies, two years later
In July 2024, 2,153 companies had the same profile as CREA MEDIC has now. Each dot stands for 6 companies, two years later.
96.0%
were still trading
2.2%
stopped another way
1.7%
went bankrupt
Test of the method
The method was tested on the 497,331 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 2.9% | 3.1% |
| 10 | 5.6% | 6.1% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 2,153 companies, not a prediction for CREA MEDIC. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Credit verdict
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Recent changes
Registered in the Peppol Directory
Reachable for e-invoices through 0208:0756788753
Registered office moved from Forest to Saint-Gilles
New registered office: Chaussée de Waterloo 157, à 1060 Saint-Gilles · Previous registered office: Rue de Fierlant 165, 1190 Forest · General meeting of 12-05-2023 · Gazette deed
Incorporation
Founder: (le fondateur) · 1,000 shares · Appointment: (director) · published on 22-10-2020 · Gazette deed
First establishment
Waterlose Steenweg 157, Sint-Gillis (bij-Brussel)
Comparable companies
same main activity, similar in size and age| Company | ||||
|---|---|---|---|---|
| CREA MEDIC Sint-Gillis (bij-Brussel) | €403,237 | €210,207 | 2.7% | - |
| Dr. Hannah Aerts Westerlo | €418,232 | €283,259 | 4.4% | - |
| Warscot Company Ittre | €584,410 | €284,917 | 64.1% | - |
| Dr. Torisaen Lien Ganshoren | €300,944 | €360,837 | 0.7% | - |
| DOKTER R. DE BAERDEMAEKER PLH Merchtem | €375,883 | €342,041 | 48.0% | - |
| Dr. Sébastien Strypstein Ingelmunster | €325,105 | €151,003 | 84.0% | - |
| Dr. Silvie Van Eycken Brasschaat | €690,923 | €170,510 | 79.7% | - |
These companies have the same main activity as CREA MEDIC: human health activities (NACE 86109). They are comparable in size and age: total assets between €301,000 and €691,000, founded between 2018 and 2022.
Official details
Source: KBO- Status
- Active since 20-10-2020Normal situation
- Activity
- Human health activitiesNACE 86109
- Establishment unit
- 2.309.230.6961060 Sint-Gillis (bij-Brussel), since 20-10-2020
- Financial year end
- 31 December
- Peppol
- Reachable since 08-01-2026
Annual accounts 2025
- ≈ €420,000estimated
- €403,237▲ 9.4%
- Filing
- Filed on 24-03-2026, 129 days before the end of the filing period
Insights on CREA MEDIC
CREA MEDIC files the micro format. That format states no turnover. The gross margin rose from €27,614 in 2020 to €210,207 in 2025.
Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.
Key facts about CREA MEDIC
- What is the company number of CREA MEDIC?
- The company number of CREA MEDIC is 0756.788.753. The VAT number is the same number with BE in front: BE 0756.788.753.
- Where is CREA MEDIC based?
- The registered office is at Waterlose Steenweg 157, 1060 Sint-Gillis (bij-Brussel).Company details
- What does CREA MEDIC do?
- According to the KBO register, the main activity is human health activities (NACE 86109).
- What is the legal form of CREA MEDIC?
- CREA MEDIC is a private limited company (BV).
- When was CREA MEDIC founded?
- CREA MEDIC was founded on 20-10-2020.
- Is CREA MEDIC still active?
- Yes, CREA MEDIC is an active enterprise in the KBO register.
- What is the turnover of CREA MEDIC?
- The turnover in financial year 2025 is ≈ €420,000. This figure is estimated from the gross margin of €210,207 and 81 comparable companies (NACE 86). It probably lies between €320,000 and €530,000.Financials
- Is CREA MEDIC profitable?
- In financial year 2025, CREA MEDIC made a profit of €156,935.
- Where can I find the annual accounts of CREA MEDIC?
- CREA MEDIC filed 6 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of CREA MEDIC due?
- CREA MEDIC must file the annual accounts for financial year 2026 by 31-07-2027.Timeline
Next steps
Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Check which of your other customers you can e-invoice via Peppol.Peppol check Compare this company with its sector.Sector benchmark See what changed in the latest annual accounts.What changed
See how customers, suppliers and banks see your own company and what to improve first.